The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Methodist Estabrook Cancer Center in Omaha has the very promising PLX4032 study that will not randomize anyone to DTIC

This topic has 2 replies, 1 voice, and was last updated 13 years, 7 months ago by SusanE.

Post

- September 22, 2010 at 5:03 pm
- Quote
tsoemd
Participant
http://www.nytimes.com/2010/09/19/health/research/19trial.html?_r=1&sq=september%2019,%202010%20and%20melanoma&st=cse&adxnnl=1&scp=1&adxnnlx=1285174989-REekyEfISOM1TDxteT1XOQ

http://www.nytimes.com/2010/09/19/health/research/19trial.html?_r=1&sq=september%2019,%202010%20and%20melanoma&st=cse&adxnnl=1&scp=1&adxnnlx=1285174989-REekyEfISOM1TDxteT1XOQ

Please refer to the above link for the New York Times article that talks about this very promising drug called PLX 4032 – a highly selective V600E BRAF kinase inhibitor that is found to be effective in melanoma. Unlike the study discussed in the NYT article, the study that we have will not randomize patients to DTIC (old chemotherapy regimen). As long as the patient's melanoma is BRAF positive, they are given PLX 4032. For more details, please contact Elisa Bomgaars, MD at 402-354-5860. We are recruiting patients still but the study will complete accrual soon.

Viewing 1 reply thread

Replies

- - September 23, 2010 at 2:58 pm
  - Quote
  SusanE
  Participant
  Creighton University has Ipilimumab coming too! Great news for Nebraska patients!
  
  Take care everyone. I appreciate this board so much. So many great people always willing to support and assist!
  
  Susan wife of Jerry Stage III
- - September 23, 2010 at 2:58 pm
  - Quote
  SusanE
  Participant
  Creighton University has Ipilimumab coming too! Great news for Nebraska patients!
  
  Take care everyone. I appreciate this board so much. So many great people always willing to support and assist!
  
  Susan wife of Jerry Stage III

Viewing 1 reply thread

You must be logged in to reply to this topic.

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Methodist Estabrook Cancer Center in Omaha has the very promising PLX4032 study that will not randomize anyone to DTIC

About the MRF Patient Forum

Popular Topics

Methodist Estabrook Cancer Center in Omaha has the very promising PLX4032 study that will not randomize anyone to DTIC

About the MRF Patient Forum

Popular Topics

Topic Tags